<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199497</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-NTS-03(08/10)</org_study_id>
    <nct_id>NCT01199497</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms, Suffering From Non-productive Cough and Acute Rhinitis</brief_title>
  <official_title>Multicenter Clinical Trial Phase III, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diphenhydramine + Pseudoephedrine + Dropropizine in the Control of Cough and the Relief of Nasal Symptoms in Subjects Above 12 Years of Age, Suffering From Non-productive Cough and Acute Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <brief_summary>
    <textblock>
      Multicenter clinical trial, phase III, controlled by active medicine, double-blind,&#xD;
      randomized, enroll 208 subjects, above 12 years old, that suffer acute inflammation upper&#xD;
      airway characterized by non-productive cough, daytime/nighttime, with duration for at least 3&#xD;
      and no more than 5 consecutive days (without systemic/topic use of medication during this&#xD;
      period) followed by nasal congestion, with or without associate other nasal symptoms&#xD;
      (sneezing, runny nose, nasal itching and/or mouth breathing). The subjects will be allocated&#xD;
      in 2 parallel groups, and will receive the medicines of study, according of the&#xD;
      randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy criteria</measure>
    <time_frame>baseline and week 24</time_frame>
    <description>The changes of lung function parameter: pre-bronchodilator forced expiratory volume in first second (FEV1) including baseline and 24th week.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy criteria</measure>
    <time_frame>baseline, week 8, 16 and 24</time_frame>
    <description>Changes in forced expiratory volume in first second (FEV1).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Nasal Congestion</condition>
  <condition>Cough</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 1</intervention_name>
    <description>fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Group 2</intervention_name>
    <description>placebo</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients over 12 years old, of both sexes;&#xD;
&#xD;
          2. Clinical condition compatible with acute rhinitis accompanied by nasal congestion;&#xD;
&#xD;
          3. Non-productive cough, daytime and/or nighttime with at least 3 and up 5 consecutive&#xD;
             days in duration;&#xD;
&#xD;
          4. Score greater than or equal to 3 points on the cough severity score (As per item&#xD;
             4.1.2);&#xD;
&#xD;
          5. Score greater than or equal to 2 points on the nasal congestion severity score (As per&#xD;
             item 4.1.3);&#xD;
&#xD;
          6. If necessary, ICF signed by a parent/representant, or in case the patient over 18&#xD;
             years old, his own signature;&#xD;
&#xD;
          7. Patient and/or representant capacity, according to investigator evaluation, for&#xD;
             compliance at the treatment and protocol requirements, fulfilling the regular visits;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-productive cough with purulent smear, fever (axilar temperature superior than&#xD;
             37,8°C/100°F), purulent runny nose and other signs and symptoms of bacteria infection&#xD;
             of upper and lower airways at 7 days before the screening/randomization visit;&#xD;
&#xD;
          2. Septal deviation level III (in any region and any nasal cavity) and/or nasal polyps or&#xD;
             other determinants conditions of nasal congestion;&#xD;
&#xD;
          3. Previous diagnosis of asthma;&#xD;
&#xD;
          4. Female patients with positive b-HCG;&#xD;
&#xD;
          5. Patients under treatment for chronic allergy;&#xD;
&#xD;
          6. Presence of purulent or mucupurulent secretion, nasal vault or mal formations (cleft&#xD;
             lip or cleft nasolabial corrected or not) in nasal vestibule;&#xD;
&#xD;
          7. Current use of systemic antibiotics for any reason;&#xD;
&#xD;
          8. Use of prohibited medicine within the prescribed period before V0 as shown in item 9.3&#xD;
             of this protocol;&#xD;
&#xD;
          9. Participation in last one year of clinical protocols;&#xD;
&#xD;
         10. Any psychiatric diseases, including major depression;&#xD;
&#xD;
         11. Presence of mental retardation from any cause;&#xD;
&#xD;
         12. Diagnosis of renal or hepatic failure;&#xD;
&#xD;
         13. History of hypersensitivity to any component of the study drugs;&#xD;
&#xD;
         14. Relatives of sponsor´s or study site´s employee;&#xD;
&#xD;
         15. Current evidence of clinically significant diseases: hematopoietic, gastrointestinal,&#xD;
             cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, autoimmune,&#xD;
             pulmonary, or another disease that block the patient participation;&#xD;
&#xD;
         16. Patient or parent/representant with a history of lack of compliance to treatment or&#xD;
             previous treatment protocols;&#xD;
&#xD;
         17. Any finding of clinical observation (anamnesis and physical exam) laboratory&#xD;
             abnormality (eg, blood glucose, blood count), disease (for example, liver,&#xD;
             cardiovascular system, lung) or therapy that, in opinion of the investigator, may&#xD;
             endanger the patient or interfere with the endpoints of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 9, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cough, acute rhinitis, nasal congestion, common cold, nasal symptoms, children.</keyword>
  <keyword>Nasal congestion and non-productive cough, with or without associate other nasal and extranasal symptoms.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

